Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Retacrit price, strengths & recalls

Brand of epoetin alfa (generic)

Pharmacies pay $1,126.83 for 10 mL of Retacrit 10000 units/mL, 1 mL injection this week, and from $225.23 to $2,247.88 across its 4 priced strengths and forms. It has 1 recall on record, none ongoing. Its official label last changed on June 26, 2025.

Brand
Pharmacies pay$1,126.83for 10 mL of 10000 units/mL, 1 mL injectionNo change in 4 weeks
Fair cash price
$1,306.35
Strengths
4
Makers
1
Updated
Nov 11

Retacrit price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
2000 units/mL, 1 mL injection Brand$22.52$225.23 / 10 mLNo change+5.2%
10000 units/mL, 1 mL injection Brand$112.68$1,126.83 / 10 mLNo change+5.0%
20000 units/mL injection Brand$224.79$2,247.88 / 10 mLNo change+5.2%
40000 units/mL, 1 mL injection Brand$448.01$1,792.03 / 4 mLNo change

Retacrit vs generic epoetin alfa

There is no generic version of Retacrit on the market yet.

GenericEpoetin alfa prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls1 recall on record

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for retacrit? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedJune 26, 2025
Version19 of 13
EffectiveJun 22, 2025
Read the label

These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clini

This drug has a boxed warning

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

See full prescribing information for complete boxed warning.

Chronic Kidney Disease:

•

In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1).

•

No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks (2.2).

•

Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions (5.1).

Cancer:

•

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (5.2).

•

Use the lowest dose to avoid RBC transfusions (2.4).

•

Use ESAs only for anemia from myelosuppressive chemotherapy (1.3).

•

ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5).

•

Discontinue following the completion of a chemotherapy course (2.4).

Perisurgery:

•

Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended (5.1).

Chronic Kidney Disease:

•

In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions (5.1)].

•

No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks [see Dosage and Administration (2.2)].

•

Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions (5.1)].

Cancer:

•

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions (5.2)].

•

To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.4)].

•

Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage (1.3)].

•

ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage (1.5)].

•

Discontinue following the completion of a chemotherapy course [see Dosage and Administration (2.4)].

Perisurgery:

•

Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration (2.5), Warnings and Precautions (5.1)].

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
BLA125545 · Hospira Inc
First approved
May 15, 2018 (8 years ago)
Latest approved change
June 4, 2024
Approved label
PDF, Jun 5, 2024
Generic makers
None on the market

Retacrit questions

How much does retacrit cost without insurance?

Pharmacies pay about $1,126.83 for 10 mL of retacrit 10000 units/mL, 1 mL injection ($112.68 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,306.35. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Retacrit?

Yes: epoetin alfa. Compare epoetin alfa prices.

Is retacrit in shortage?

No shortage is reported for retacrit right now. We check the national shortage list every day.

Has retacrit been recalled?

1 recall on record, none ongoing. Recalls name specific lots - check yours.

When did the retacrit label last change?

The official label was last updated on June 26, 2025 (version 19). See what changed.

Talk about retacrit

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.